Ritu Baral

I wanted to ask you a little more about your comments around first-line use and second-line use

I wanted to ask about the gross-to-net pattern over 2026. Tolga, you mentioned mid-single digits. Is that going to be sort of a stepwise adjustment in Q1 and then flat through the rest of the year,...

what degree of commercial investment is needed in Europe to expand beyond the PN indication

what trends are you seeing in the V122I variant population

can you speak a little to the type of patient or profile of patient that is making up that first line use

What sort of potential advantage could that give you or not, either detailing the product or with payers

any thoughts on right now, whether breadth of prescribers or depth of prescribing within prescribers is more important to increasing demand?

When will you and when will we get more clarity on refinement of this $1 billion-plus level

What threshold do you see for that payer coverage that we should keep in mind going forward?

do you have an idea at this point about what sort of prior authorizations outside diagnosis or two exacerbations might be

Were there any surprises in the mid-cycle review meeting? And then on the TPIP side, what are your thoughts on either the Phase 3 design

are you going to have to accommodate more in prior authorizations or what you are expecting prior authorizations to be

Is there something in that data set that would let you feature a potential reduction in cough or cough burden